References
Anand R, Moore JL, Srinivason A, Kalyanaraman V, Francis D, et al. Ansamycin inhibits replication and infectivity of HTLV-III/LAV. Session 27, International Conference on Acquired Immunodeficiency Syndrome (AIDS) Atlanta, 1985
Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for AIDS. Science 220: 268–271, 1983
Broder S, Yarchoan R, Collins JM, Lane HC, Markham PD, et al. Effects of suramin on HTLV-III/LAV infection presenting as Kaposi’s sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication in vivo. Lancet 2: 627–630, 1985
Burke P. Doctors hopeful of AIDS “cure”. New York Native 9-15: 10, 1985
Chermann J-C, Sinoussi FC, Jasmin C. Inhibition of RNA-dependent DNA polymerase of murine oncornaviruses by ammonium-5-tungsto-2-antimoniate. Biochemical and Biophysical Research Communications 65: 1229–1236, 1985
Chou TC, Talay P. Quantitative analysis of dose-effect relationships. The combined effects of multiple drugs on enzyme inhibitors. Advances in Enzyme Regulation 22: 27–55, 1984
De Clercq E. Suramin: a potent inhibitor of reverse transcrtiptases. Cancer Letters 8: 9–22, 1979
De Clercq E. Specific targets for antiviral drugs. Biochemical Journal 205: 1–13, 1982
Dormont D, Spire B, Barre-Sinoussi F, Montagnier L, Chermann JC. Inhibition of RNA-dependent DNA polymerases of AIDS and SAIDS retrovirus by HPA-23 (ammonium-21-tungsto-9-antimoniate). Annales de L’Institut Pasteur/Virologie 136E: 75–83, 1985
Goswami DB, Borek E, Sharma OK, Fujitaki J, Smith RA. The broad spectrum antiviral agent ribavirin inhibits capping of RNA. Biochemical and Biophysical Research Communications 89: 830–836, 1979
Hawking F. Suramin: with special reference to onchocerciasis. Advances in Pharmacology and Chemotherapy 15: 289, 1974
Hirsch MS, Kaplan JC. Prospects for therapy of HTLV-III infection. Annals of Internal Medicine, 103: 750–755, 1985
Ho DD, Hartshorn KL, Rota TR, et al. Recombinant human interferon alpha-A suppresses HTLV-III replication in vitro. Lancet 1: 602–604, 1985
Jasmin C, Chermann JC, Herve G, Teze A, Souchay P, et al. In vivo inhibition of murine leukemia and sarcoma viruses by the heteropoly-anion 5-tungsto-2-antimoniate. Journal of the National Cancer Institute 53: 469–474, 1974
Lin T-S, Prushoff WH. Synthesis and biological activity of several amino analogues of thymidine. Journal of Medicinal Chemistry 21: 109–122, 1978
Lotze MT. Treatment of immunologic disorders in AIDS. In DeVita et al. (Eds) AIDS, Lippincott, Philadelphia, 1985
Mathur-Waugh U, Enlow RW, Spigland I, Winchester RJ, Sachs HS, et al. Longitudional study of persistent generalized lymphadenopathy in homosexual men: relation to AIDS. Lancet 1: 1033–1038, 1984
McCormick JB, Getchell JP, Mitchell SW, Hicks DR. Ribavirin suppresses replication of lymphadenopathy-associated virus in cultures of human adult T lymphocytes. Lancet 2: 1367–1369, 1984
Mitsuya H, Popovic M, Yarchoan R, Matsushita S, Gallo RC, et al. Suramin protection of T-cells in vitro against infectivity and cytopathic effect of HTLV-III. Science 226: 172–174, 1984
Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Nusinoff Lehrman S, et al. 3′-azido-3′-deoxythymidine (BW A509U): a new antiviral agaent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus III/lymphadenopathy associated virus in vitro. Proceedings of the National Academy of Sciences 82: 7096–7100, 1985
Popovic M, Sarngadharan MG, Read E, Gallo RC. Detection, isolation and continous production of a cytopathic retrovirus (HTLV-II) from patients with AIDS and pre-AIDS. Science 224: 497–500, 1984
Rozenbaum W, Dormont D, Spire B, Vilmer E, Gentilini M, et al. Antimoniotungstate (HPA-23) treatment of three patients with AIDS and one with prodrome. Lancet 1: 450–451, 1985
Sandström EG, Kaplan JC, Byington RE, Hirsch MS. Inhibition of human T-cell lymphotropic virus type III by phosphonoformate. Lancet 1: 1480–1482, 1985
Sarin PS, Taguchi Y, Sun Y, Thornton A, Gallo RC, et al. Inhibition of HTLV-III/LAV by Foscarnet. Biochemical Pharmacology, in press, 1986
Shannon WM. Selective inhibition of RNA viruses replication in vitro and evaluation of candidate antiviral agents in vitro. Annals of the New York Academy of Sciences 284: 472, 1977
Shannon WM. Mechanism of action and pharmacology: chemical agents. In Galasso (Ed.) Antiviral agents and viral diseases of man, 2nd ed, Raven Press, New York, 1984
Sundqvist B, Larner E. Phosphonoformate inhibition of visna virus replication. Journal of Virology 30: 847–851, 1978
WHO. Acquired immune deficiency syndrome (AIDS). Weekly Epidemiological Record 60: 305–312, 1985
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sandström, E. Antiviral Drugs for AIDS. Drugs 31, 463–466 (1986). https://doi.org/10.2165/00003495-198631060-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198631060-00001